SEC Comment Letter 0000000000-24-014055 to Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687) (RNAC)

Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687)
Date: Dec. 19, 2024 · CIK: 0001453687 · Accession: 0000000000-24-014055

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-283803

Date

December 19, 2024

Author

Division of

Form

UPLOAD

Company

Cartesian Therapeutics, Inc. (RNAC) (CIK 0001453687)

Letter

Re: Cartesian Therapeutics, Inc. Registration Statement on Form S-3 Filed December 13, 2024 File No. 333-283803 Dear Blaine Davis:

December 19, 2024

Blaine Davis Chief Financial Officer Cartesian Therapeutics, Inc. 7495 New Horizon Way Frederick, MD 21703

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Sarah Griffiths, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           December 19, 2024

Blaine Davis
Chief Financial Officer
Cartesian Therapeutics, Inc.
7495 New Horizon Way
Frederick, MD 21703

        Re: Cartesian Therapeutics, Inc.
            Registration Statement on Form S-3
            Filed December 13, 2024
            File No. 333-283803
Dear Blaine Davis:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Doris Stacey Gama at 202-551-3188 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Sarah Griffiths, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io